Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2/3 trial

Journal of Dermatology

Volumn 39, Issue 9, 2012, Pages 761-769

  Nakagawa, Hidemi ^a   Schenkel, Brad ^b   Kato, Mai ^c   Kato, Takeshi ^d   Igarashi, Atsuyuki ^e  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Janssen Scientific Affairs LLC   (United States)

^c Division of Biostatistics and Data Management   (Japan)

^d Janssen Pharmaceutical KK   (Japan)

^e Kanto Teishin Hospital   (Japan)

Author keywords

interleukin 12 23 p40; Japanese; psoriasis; quality of life; ustekinumab

Indexed keywords

PLACEBO; USTEKINUMAB;

ACADEMIC ACHIEVEMENT; ADULT; ARTICLE; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; HUMAN RELATION; JAPANESE; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE;

EID: 84865634236     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2012.01521.x     Document Type: Article

References (46)

1. Schön MP, Boehncke WH,. Psoriasis. N Engl J Med 2005; 352: 1899-1912.
2. Yip SY,. The prevalence of psoriasis in the mongoloid race. J Am Acad Dermatol 1984; 10: 965-968.
3. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-465.
4. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM,. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-895.
5. Gottlieb AB, Dann F,. Comorbidities in patients with psoriasis. Am J Med 2009; 122: 1150.
6. Hong J, Koo B, Koo J,. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther 2008; 21: 54-59.
7. Kotrulja L, Tadinac M, Joki-Begi NA, Gregurek R,. A multivariate analysis of clinical severity, psychological distress and psychopathological traits in psoriatic patients. Acta Derm Venereol 2010; 90: 251-256.
8. Magin P, Adams J, Heading G, Pond D, Smith W,. Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative study. Scand J Caring Sci 2008; 22: 430-436.
9. Gupta MA, Gupta AK,. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846-850.
10. Picardi A, Mazzotti E, Pasquini P,. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol 2006; 54: 420-426.
11. Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M,. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989-1004.
12. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y,. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-392.
13. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM,. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41 (3 Pt 1): 401-417.
14. Fukuchi O, Finlay AY, Ohta A, et al. Development of the Japanese version of the Psoriasis Disability Index (PDI), the Psoriasis Specific QOL Index: results of the validation study. Jpn J Dermatol 2006; 116: 1583-1591 (in Japanese).
15. Hirabe M, Hasegawa T, Fujishiro Y, Kigawa M, Fukuchi O, Nakagawa H,. Impact of longitudinal changes in psoriasis skin symptoms on quality of life. Jpn J Dermatol 2011; 121: 875-882 (in Japanese).
16. Lee YW, Park EJ, Kwon IH, Kim KH, Kim KJ,. Impact of psoriasis on quality of life: relationship between clinical response to therapy and change in health-related quality of life. Ann Dermatol 2010; 22: 389-396.
17. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-146.
18. Kimball AB, Guérin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011; 25: 157-163.
19. Reich K, Segaert S, Van de Kerkhof P, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 2009; 219: 239-249.
20. Reich K, Schenkel B, Zhao N, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2. J Dermatolog Treat 2011; 22: 337-347.
21. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008; 159: 704-710.
22. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
23. Takahashi H, Nakamura K, Kaneko F, Nakagawa H, Iizuka H,; Japanese Society for Psoriasis Research. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol 2011; 38: 1125-1129.
24. Asahina A, Nakagawa H, Etoh T, Ohtsuki M,; Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
25. Torii H, Nakagawa H,; Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-49.
26. Torii H, Nakagawa H,; Japanese Infliximab Study Investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol 2011; 38: 321-334.
27. Tsai T-F, Ho J-C, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63: 154-163.
28. Huang PH, Liao YH, Wei CC, Tseng YH, Ho JC, Tsai TF,. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study. J Eur Acad Dermatol Venereol 2008; 22: 923-930.
29. Krueger GG, Langley RG, Leonardi C, et al.; CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-592.
30. Leonardi CL, Kimball AB, Papp KA, et al.; PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
31. Papp KA, Langley RG, Lebwohl M, et al.; PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
32. Griffiths CE, Strober BE, van de Kerkhof P, et al.; ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
33. Igarashi A, Kato T, Kato M, Song M, Nakagawa H,; the Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque- type psoriasis: long-term results from a Phase 2/3 clinical trial. J Dermatol 2011; doi: 10.1111/j.1346-8138.2011.01347.x.
34. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
35. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
36. Finlay AY, Khan GK,. Dermatology Life Quality Index. Information & conditions concerning use. The USA Library of Congress, registration number: TXU 608406, registration date: 6 December 1993.
37. Finlay AY,. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
38. Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J,. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin 2008; 24: 1237-1254.
39. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D,. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141-155.
40. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
41. Finlay AY, Kelly SE,. Psoriasis-an index of disability. Clin Exp Dermatol 1987; 12: 8-11.
42. Holm S,. A simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6: 65-70.
43. Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24: 17-22.
44. Lewis VJ, Finlay AY,. Two decades experience of the psoriasis disability index. Dermatology 2005; 210: 261-268.
45. Mazzotti E, Barbaranelli C, Picardi A, et al. Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol 2005; 85: 409-413.
46. Berthelot J-M, Maugars Y, Abgrall M, Prost A,. Interindividual variations in beliefs about the placebo effect: a study in 300 rheumatology inpatients and 100 nurses. Joint Bone Spine 2001; 68: 65-70.